chart.ashx?t=rnn&ta=1&p=d&s=l
Rexahn Pharmaceuticals, Inc. (Rexahn) is development-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. Rexahn is developing targeted cancer drugs and nano-medicines for the treatment of cancer. The Company’s clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant drug, and Zoraxel, an erectile dysfunction (ED) drug. Rexahn’s pre-clinical pipeline includes RX-0201-Nan, RX-0047-Nano and Nano-polymer Anticancer Drugs.